Real‐World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort

Haemophilia · Published 2026-04-24 · DOI 10.1111/hae.70290

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1111/hae.70290

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B · Haemophilia · 2026 · Same journal
• Gait Pattern at Different Speeds in Persons With Haemophilia · Haemophilia · 2026 · Same journal
• Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis · Haemophilia · 2026 · Same journal
• Seventh Åland Island Meeting on von Willebrand Disease · Haemophilia · 2026 · Same journal
• The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐decay: Argentinean and International Series · Haemophilia · 2026 · Same journal
• Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11‐Year Retrospective Cohort Study · Haemophilia · 2026 · Same journal
• Successful Treatment of Heavy Menstrual Bleeding in a Woman With Mild Haemophilia A Using Efanesoctocog Alfa · Haemophilia · 2026 · Same journal
• Weight‐Bearing Lunge Test in Young Patients With Haemophilia and Limited Joint Damage: Reliability and Functional Associations for Ankle Assessment · Haemophilia · 2026 · Same journal
• Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database · Haemophilia · 2026 · Same journal
• Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND‐ed · Haemophilia · 2026 · Same journal